ADTRAN
Adtran today announced that telMAX is leveraging its scalable, programmable fiber access technology as it extends its high-speed broadband services to many more communities. The Canadian service provider is harnessing Adtran’s Mosaic CP microservices platform integrated with GLDS BroadHub® subscriber management platform to enable rapid, cost-effective expansion of its network. With advanced automation features, the technology streamlines network management and service activation, empowering telMAX to enhance service delivery, troubleshooting and customer care. The new solution is built on Adtran’s compact SDX 6000 Series of Combo PON optical line terminals (OLTs), along with Adtran’s multigigabit XGS-PON optical network terminals, designed for the most bandwidth-intensive subscribers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716856855/en/
Adtran’s fiber access technology is helping telMAX rapidly expand into new areas. (Photo: Business Wire)
“At telMAX, our mission is to be the premier telecommunications provider in Canada, offering the fastest internet services and the best customer care experience. Leveraging Adtran’s technology has been instrumental in this goal. It’s enabled us to deliver exceptional speed and service, helping us earn recognition from PCMag as Canada’s Fastest ISP for the last two years running,” said Stuart Robert, president of telMAX. “Our new fiber access solution empowers us to perform many operations remotely, ensuring swift, trouble-free installations for our subscribers. The capability to quickly deploy and activate equipment optimizes productivity and significantly reduces manual efforts and operational costs. This efficiency enables us to rapidly expand into new areas, creating ‘fiberhoods’ where residents can enjoy exclusive, lightning-fast internet connectivity.”
telMAX is extending its network to reach more communities across the Greater Toronto Area. Today, they serve a growing customer base in the areas of Newmarket, Stouffville, Brooklin and Aurora. Leveraging Adtran’s technology, including the Mosaic CP platform and SDX Series of OLTs integrated with the GLDS BroadHub® subscriber management and service delivery platform, telMAX is well-equipped to meet the demands of these new markets. The integration allows for real-time adjustments to network conditions and rapid responses to customer demands, significantly enhancing operational efficiencies and scalability. It eliminates swivel-chair operations, removing operational barriers that can slow down workflows, complicate fiber rollouts and introduce friction into customer interactions. By enhancing service quality, minimizing downtime and ensuring heightened network reliability, telMAX will be able to provide superior connectivity and support to its expanding customer base.
“This deployment gives telMAX a more agile and customer-focused network, significantly increasing overall satisfaction as they bring ultra-fast full-fiber broadband to more households and businesses in Southern Ontario,” commented John Scherzinger, GM of Americas sales at Adtran. “Our technology is powering telMAX’s rapid growth, enabling them to expand their network while fostering community development. Seamless connectivity, reaching every street and neighborhood, will bridge the connectivity gap and enhance community engagement. Today’s digitally driven world demands intelligent, flexible networks that guarantee superior service quality. By adopting our Mosaic CP and GLDS’s BroadHub®, telMAX is at the forefront of efforts to transform networks to be more responsive to evolving subscriber needs and expectations.”
“Pairing the subscriber-centered functionality of our BroadHub® platform with the control and orchestration capabilities of Adtran’s Mosaic CP enables telMAX to streamline service delivery and elevate the customer experience. BroadHub® is designed to provide comprehensive customer management and billing solutions that manage the complete customer lifecycle. This integration allows telMAX to simplify operations and efficiently deliver superior customer care,” noted Adam Ross Hill, partner alliance manager at GLDS. “Today’s broadband subscribers expect interactions with their service provider to be efficient and accurate. Using our platform, telMAX can automate service delivery and save their technicians and customers valuable time. In addition to boosting subscriber satisfaction, BroadHub® also offers a cost-effective way to enhance operational efficiency, supporting telMAX’s growth and commitment to community empowerment.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240716856855/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom